Skip to main content

Day: December 13, 2022

Aesther Healthcare Acquisition Corp. Announces Intention to Extend Period to Consummate Business Combination

New York, NY and Providence, RI, Dec. 13, 2022 (GLOBE NEWSWIRE) — As previously announced, on August 31, 2022, Aesther Healthcare Acquisition Corp. (“Aesther”) (NASDAQ: AEHA) entered into definitive merger agreement with Ocean Biomedical, Inc. Aesther announced today that its Board of Directors has approved an extension of the period of time available to Aesther to consummate a business combination by three months from December 16, 2022 to March 16, 2022 (the “Second Extension”), as permitted under Aesther’s governing documents. In connection with the Second Extension, Aesther’s sponsor, Aesther Healthcare Sponsor, LLC, has agreed to deposit an aggregate of $1,050,000 into Aesther’s Trust account for its public stockholders, representing $0.10 per public share, by December 16, 2022, which will be in the form of a loan. Aesther’s...

Continue reading

Arqit announces a partnership with Dell Technologies to bring quantum-safe solutions to its customers

ARLINGTON, Va., Dec. 13, 2022 (GLOBE NEWSWIRE) — Arqit Quantum Inc. (Nasdaq: ARQQ, ARQQW) (“Arqit”), a leader in quantum-safe encryption announces that it has signed with Dell Technologies (“Dell”) a “Dell OEM Engineered Solutions Pilot Agreement”. Dell agrees to preload Arqit’s QuantumCloud™ software on selected Dell hardware devices, enabling Dell sales teams to sell the combined hardware and software as a single SKU to address existing and new customer needs. The initial target market is the US Federal Government, including the Department of Defense (DoD), the Federal Civilian Agencies and the Intelligence Community. Dell sales teams will be able to offer Arqit QuantumCloud™ software and Arqit sales teams will be able to offer Dell hardware and services in their sales portfolios.  Arqit’s QuantumCloud™ is...

Continue reading

Endonovo Launches Telehealth Initiative

Expands Patient Education, Access to Non-Opioid Options for Pain Management Los Angeles, CA, Dec. 13, 2022 (GLOBE NEWSWIRE) — Endonovo Therapeutics, Inc. (OTCQB: ENDV) today announced the launching of a new initiative to utilize its telehealth platform to educate and provide prescription and “over the counter” non-opioid pain reduction options. The Endonovo Telehealth platform will provide alternative pain management options through its direct-to-consumer sales of prescription and non-prescription uses of their SofPulse® Pulsed Electro Magnetic Frequency (PEMF) medical device proven to reduce opioid use. Shortage of Physicians “There is a massive and acute shortage of primary care physicians and other healthcare specialists prompting the need for patient information and product distribution systems which only a telehealth platform...

Continue reading

Correction: Awilco Drilling PLC – Change of ISIN and method of VPS registration – reverse split – transfer of listing to Euronext Growth – contemplated private placement

Reference is made to the announcement on 23 November 2022 that Awilco Drilling PLC (“Awilco Drilling”) intended to apply for a transfer of its listing from Oslo Børs to Euronext Growth Oslo and to the announcement on 1 November 2022 that Awilco Drilling will change its structure of VPS registration to Sponsored Norwegian Depository Receipts (“SNDRs”). The first day of trading on Euronext Growth Oslo is expected to occur on 16 December 2022 and the last day of trading on Oslo Børs is expected to be on 15 December 2022. Following the listing on Euronext Growth Oslo, Awilco Drilling expects to carry out an equity offering of approx. USD 10 million, expected to be structured as combination of a private placement and a subsequent repair offering. As from the first day of trading on Euronext Growth Oslo, Awilco Drilling...

Continue reading

Puma Exploration Samples More High-Grade Gold* at the Jaguar Gold Zone

Figure 1 Grab samples collected at surface at the Jaguar Gold ZoneFigure 2 Williams Brook property main gold zonesRIMOUSKI, Quebec, Dec. 13, 2022 (GLOBE NEWSWIRE) — Puma Exploration Inc. (TSXV: PUMA, OTCQB: PUMXF) (the “Company” or “Puma”) is pleased to announce up to 34.70 g/t Au in grab samples* collected at the Jaguar Gold Zone (“JGZ”) this fall as part of the Company’s ongoing surface exploration program at its 100%-owned Williams Brook Gold Project in Northern New Brunswick. Results are consistent with widespread epithermal/orogenic gold systems, and Puma plans to extend stripping and launch an inaugural drill program at the JGZ in 2023. Figure 1: Grab samples* collected at surface at the Jaguar Gold Zone is available at the following address:https://www.globenewswire.com/NewsRoom/AttachmentNg/15d5cb3c-54f3-40d1-90a3-372d6eeec852 *The...

Continue reading

Global Hair Styling Tools Market to Worth $40.5 Billion by 2028 | Hair Straightener Generates Over 35% Revenue | Dyson, Revlon and Philips are Most Adored Brands

Global hair styling tools market was valued at USD 19.2 billion in 2021, and it is expected to reach a value of USD 40.5 billion by 2028, at a CAGR of more than 3.4% over the forecast period (2022–2028). Westford, USA, Dec. 13, 2022 (GLOBE NEWSWIRE) — The report attributes hair styling tools market growth to a number of factors, including an increase in the number of women working outside the home, a rise in disposable income levels, and a growing trend towards self-expression and individualism. SkyQuest’s analysis also found that the majority of hair styling tool users are young adults, aged 18-34. This demographic is particularly important for manufacturers to target, as they are more likely to be early adopters of new products and trends. The report concludes with some recommendations for manufacturers in the global hair styling...

Continue reading

Global Laser Engraving Machine Market to Surpass Valuation of $6.19 Billion by 2028 | Low-Cost Chinese Manufacturers Have Intensified Market Competition

Global laser engraving machine market was valued at USD 3.5 billion in 2021, and it is expected to generate revenue of USD 6.19 billion by 2028, at a CAGR of more than 8.5% over the forecast period (2022–2028). Westford, USA, Dec. 13, 2022 (GLOBE NEWSWIRE) — The laser engraving machine market is growing rapidly, with sales expected to reach $6.19 billion by 2028. This growth can be attributed to the rising demand for these machines from various end-use industries, such as advertising, art and crafts, and education. Laser engraving machines are widely used in advertising industry for creating signage and displays. They are also used in art and crafts for engraving designs on metals, glass, wood, and leather. These machines are increasingly being used in the education sector for engraving logos and texts on award certificates and...

Continue reading

vTv Therapeutics Appoints Biotech Industry Veteran Steven Tuch as Chief Financial Officer

Steven Tuch, Chief Financial Officer Steven Tuch, Chief Financial OfficerSteven Tuch, Chief Financial Officer HIGH POINT, N.C., Dec. 13, 2022 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D), today announced the appointment of Steven Tuch as Chief Financial Officer, effective immediately. “Steven’s success in capital raising and business development, combined with his range of work in the life science and healthcare industry, makes us confident that he is an excellent fit for the position and our needs,” said Paul Sekhri, President and Chief Executive Officer of vTv Therapeutics. “We anticipate that he will play a pivotal role as we actively prepare to initiate, then execute on, our Phase...

Continue reading

ORIC Pharmaceuticals Presents Preclinical Data Demonstrating ORIC-533 as a Potential Best-in-Class CD73 Inhibitor at the 64th American Society of Hematology (ASH) Annual Meeting

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 13, 2022 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, presented preclinical ORIC-533 data demonstrating a potential best-in-class CD73 inhibitor profile for the treatment of multiple myeloma. “ORIC-533 continues to demonstrate strong potency in reducing adenosine generation and thereby overcoming immune suppression and restoring lysis of multiple myeloma cells as a single agent in ex vivo models,” said Jacob M. Chacko, MD, chief executive officer. “We look forward to sharing initial clinical data from the ongoing Phase 1b study of ORIC-533 in patients with multiple myeloma in the first half of 2023.” The ASH presentation focused on ex vivo proof-of-concept...

Continue reading

Pan American Energy Announces Filing of Notice of Intent to Conduct Re-Entry Well Exploration Drilling at the Green Energy Lithium Project (Utah)

Pan American Energy advances permitting for re-entry well exploration drilling in the Paradox Basin, targeting Cane Creek Federal 11-1 wellFigure 1 Re-Entry Drill Hole LocationsCALGARY, Alberta, Dec. 13, 2022 (GLOBE NEWSWIRE) — Pan American Energy Corp. (the “Company” or “Pan American”) (CSE: PNRG) (OTC PINK: PAANF) (FRA: SS6) is pleased to announce that the Company has submitted a Notice of Intent to the Bureau of Land Management (“BLM”), Moab District Field Office, for re-entry well exploration drilling at its 4,160 acre Green Energy Lithium Project, located in the Paradox Basin, Utah. The Company is proposing to re-enter the previously drilled and plugged Cane Creek Federal 11-1 sample well on federal surface and minerals lands managed by the BLM Moab Field Office within Grand County, Utah, approximately 13.5 miles west...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.